GSK to advance Voltarol’s market dominance in UK
This article was originally published in OTC Bulletin & The Rose Sheet
GlaxoSmithKline (GSK) Consumer Healthcare is set to spend big on marketing and innovation to enable its Voltarol brand to capture a 50% share of the UK’s OTC topical analgesic market.
You may also be interested in...
A new project devised by Pfizer and the Wellcome Trust aims to tackle antimicrobial resistance (AMR) in four sub-Saharan African countries by using real world data to track resistance patterns and allow patients to be treated more successfully. Wellcome’s Gemma Buckland-Merrett explains how the project will work and how it could help other industry partners and governments to generate valuable data in the fight against AMR.
Private equity group Carlyle has acquired 20% of Piramal’s pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Mundipharma has announced the European Commission’s extension of the indications for Invokana to include renal outcomes data from the Phase III CREDENCE study.